Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on October 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Alkeus reported audited FY2025 financials, relevant to Tarsus investors because the exhibit appears to provide acquisition-related target disclosures.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Alkeus reported audited FY2025 financials, relevant to Tarsus investors because the exhibit appears to provide acquisition-related target disclosures
- Going-concern warning: substantial doubt about Alkeus’s ability to continue operations without additional financing
- Cash $84.0M versus $57.6M, but operating cash burn increased to $48.2M from $18.9M
- Net loss widened to $49.8M from $18.5M, with research and development expense rising to $32.4M
- Series B-3 financing generated $74.8M net proceeds, while accumulated deficit reached $74.3M
Item EX-99.2 · Exhibit EX-99.2
- Nine-month net loss $35.3M, with operating expenses of $37.0M and no product revenue
- Cash fell to $48.7M from $84.0M, while operating cash burn reached $35.5M
- Going-concern risk: additional financing needed to fund operations for at least twelve months from September 3, 2026
- Accumulated deficit reached $109.6M, highlighting substantial future funding requirements
- July 31, 2026 merger agreement with Tarsus creates a potential strategic liquidity event for Alkeus shareholders
Item EX-99.3 · Exhibit EX-99.3
- Alkeus merger closed September 4, 2026, adding gildeuretinol, a late-stage IPR&D asset, but no current revenue
- Tarsus paid preliminary consideration of $585.9M, including $244.6M cash, 2,769,696 shares, and $95.9M contingent liabilities
- Financing added approximately $119.0M net cash through 2,098,519 shares and 133,625 pre-funded warrants, partially funding the acquisition
- Pro forma 2025 results include $564.8M IPR&D expense, producing net loss of $696.1M and loss per share of $14.83
- Future obligations include $250.0M regulatory, $100.0M commercial milestones, and uncapped tiered royalties below 5.0% initially
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.